Wearables as Cancer Monitors; No China Price Break; Cancer Mystery in Appalachia

Wearable devices have the potential to become major contributors to precision cancer care. (UVA Health)

Biological therapy — such as monoclonal antibodies and antibody-drug conjugates — dominates the therapeutic landscape for solid tumors, accounting for about two thirds of all drugs. (GlobalData)

Preclinical studies suggest that diabetes may accelerate the growth of multiple myeloma cells. (Memorial Sloan Kettering Cancer Center, Blood Advances)

Hopes for cheaper cancer drugs from China took a hit, as Coherus BioSciences “will not engage in heavily discounted pricing” for toripalimab (Loqtorzi), the first China-developed anti-PD-1 drug, expected to launch in the U.S. early next year. (FiercePharma)

The American Society of Clinical Oncology has launched a certification program for patient-centered cancer care standards.

For reasons not yet clear, cervical cancer incidence and mortality are twice the national average in Appalachian Kentucky. (JAMA Network Open)

More progress toward a blood test that can detect the earliest signs of developing cancer. (The Rockefeller University, Cancer Discovery)

Responding to doctors’ concern about access to their personal information, the medical website Doximity has introduced DocDefender, a free service that removes doctors’ addresses and phone numbers from public websites. (CNBC)

Artificial intelligence using scans was almost twice as accurate as a biopsy for determining the aggressiveness of certain sarcomas. (The Guardian, Lancet Oncology)

The American Society for Radiation Oncology (ASTRO) expressed “deep disappointment” in a final Medicare ruling that would cut an additional 2% from reimbursement for radiation oncology; ASTRO called for a legislative solution for declining Medicare physician payments.

Please enable JavaScript to view the

comments powered by Disqus.